Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

fluticasone-umeclidinium-vilanterol

fluticasone-umeclidinium-vilanterol
  • Non-formulary
  • Therapeutic Interchange
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Trelegy Ellipta POWDER, INHALATION 100 mcg-62.5 mcg-25 mcg/act, 200 mcg-62.5 mcg-25 mcg/act    


Comments:

Due to national shortage of the nebulization solutions, the formulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products will automatically return to their original formulary status. See Albuterol/Duoneb Shortage Mitigation for more information. (Updated Feb 2023)


Ordered Formulation Therapeutic Interchange Notes

fluticasone-umeclidinium-vilanterol (Trelegy Ellipta)                         

  • 100 mcg-62.5 mcg-25 mcg/1 actuation once daily

 

  • 200 mcg-62.5 mcg-25 mcg/1 actuation once daily
albuterol-ipratropium (DuoNeb) AND budesonide (Pulmicort Respules)
  • albuterol-ipratropium 3 mg-0.5 mg QID PLUS budesonide 250 mcg neb BID
  • albuterol-ipratropium 3 mg-0.5 mg QID PLUS budesonide 500 mcg neb BID 
Inpatient may use own inhaler.

Trelegy Ellipta medication guide


Inpatient may use own inhaler.

 


Reviewed: 25 June 19 (Trelegy Ellipta)

Updated: February 24 (Trelegy Ellipta Interchange)

Fluticasone umeclidinium vilanterol (Trelegy Ellipta)


Last updated: Apr. 11, 2024







This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.